NURS 5336 Family 3- Final Exam Questions and Answers
1. Which |of |the |following |is |a |high |intensity |statin |therapy
|Rosuvastatin |20-40
2. Depression |is |more |common |if |there |is |a |family |history
|True
3. Clinicians |are |greatly |concerned |with |liver |disease |in |patients |taking |statins
Check |ALT |(alanine |aminotransferase) |at |baseline. |Repeat |only |if |symptoms |of |hepatotoxicity |occur
|(from |prescriber’s |letter |in |module)
With | the | use | of | a | lipid-lowering | resin, | which | of | the | following | enzymes | should | be
| periodically |monitored?
A. ALP
B. LDH
C. AST
D. No | particular | monitoring | is | recommended.
4. Drug |category |most |likely |to |cause |hypoglycemia
|Sulfonylureas
5. In |2016 |caring |for |patients |who |are |candidates |for |statin |therapy |our |most |important |guideline.
|Decreasing |global |risk, |not |a |specific |LDL |target |(from |prescriber’s |letter |in |module)
6. Components |of |tobacco |use |cessation
|Ask, |Advise, |Assess, |Assist, |Arrange |Model
7. USPT |screen |all |the |following |sexually |active |women |EXCEPT |A
|woman |in |a |mutually |monogamous |relationship
8. Metabolic |syndrome |significantly |increased |risk |for:
Cardiovascular |disease
9. When |prescribing |a |meal |plan |for |a |type |II |diabetic |advise |the |patient |that |the |macronutrient
|that |provides |post |prandial |hyperglycemia:
Carbohydrates
10. In |the |person |with |hypertension, |which |of |the |following |would |likely |yield |the |greatest
|potential |reduction |in |BP
in |a |patient |with |a |BMI |of |30 |kg/m2?
A. 10-kg |(22-lb) |weight |loss
B. dietary |sodium |restriction |to |2.4 |g |(6 |g |NaCl) |per |day
C. regular |aerobic |physical |activity, |such |as |30 |minutes
|of |brisk |walking |most |days |of |the |week
D. moderation |of |alcohol |consumption
, 11. A |middle-aged |woman |who |has |taken |therapeutic |dose |of |lorazepam |for |the |past |6 |years
|wishes |to |stop |taking
the |medication. |You |advise |her |that:
A. she |can |discontinue |the |drug |immediately |if |she |believes |it |no |longer |helps |with |her
|symptoms.
B. rapid |withdrawal |in |this |situation |can |lead |to |tremors |and |hallucinations.
C. she |should |taper |down |the |dose |of |the |medication |over |the |next |week.
D. gastrointestinal |upset |is |typically |reported
12. Patient |forgetful |would |benefit |from |a |med |that |has |a |long |half |life
|Zoloft
Celexa
Fluoxetine |(Prozac) |has |the |longest |half |life
13. Add |basal |insulin |to |a |patient |already |taking |3 |oral |meds. |Reduce |which |med?
|Metformin
Glipizide |(sulfonylurea)
|TZD
DPP |4 |inhibitor
According |to |slide |13 |on |PEARL
14. Lipid |lowering |moderate |intensity |statins
|Moderate |dose |statin |(avg |LDL |reduction |30-50%)
|Mimi |chose |20-30%
15. An |example |of |an |appropriate |question |to |pose |to |a |person |with |obesity |who |is |in |the
|precontemplation
change |stage |is:
A. “How |do |you |feel |about |your |weight?”
B. “What |are |barriers |you |see |to |losing |weight?”
C. “What |is |your |personal |goal |for |weight |loss?”
D. “How |do |you |envision |my |helping |you |meet |your |weight |loss |goal?”
16. Which |disorder |seen |in |uncontrolled |DM |with |increased |glucose?
|Pancreatitis
Hypothyroidism |???
|Gall |stones
High |triglycerides
1. Which |of |the |following |is |a |high |intensity |statin |therapy
|Rosuvastatin |20-40
2. Depression |is |more |common |if |there |is |a |family |history
|True
3. Clinicians |are |greatly |concerned |with |liver |disease |in |patients |taking |statins
Check |ALT |(alanine |aminotransferase) |at |baseline. |Repeat |only |if |symptoms |of |hepatotoxicity |occur
|(from |prescriber’s |letter |in |module)
With | the | use | of | a | lipid-lowering | resin, | which | of | the | following | enzymes | should | be
| periodically |monitored?
A. ALP
B. LDH
C. AST
D. No | particular | monitoring | is | recommended.
4. Drug |category |most |likely |to |cause |hypoglycemia
|Sulfonylureas
5. In |2016 |caring |for |patients |who |are |candidates |for |statin |therapy |our |most |important |guideline.
|Decreasing |global |risk, |not |a |specific |LDL |target |(from |prescriber’s |letter |in |module)
6. Components |of |tobacco |use |cessation
|Ask, |Advise, |Assess, |Assist, |Arrange |Model
7. USPT |screen |all |the |following |sexually |active |women |EXCEPT |A
|woman |in |a |mutually |monogamous |relationship
8. Metabolic |syndrome |significantly |increased |risk |for:
Cardiovascular |disease
9. When |prescribing |a |meal |plan |for |a |type |II |diabetic |advise |the |patient |that |the |macronutrient
|that |provides |post |prandial |hyperglycemia:
Carbohydrates
10. In |the |person |with |hypertension, |which |of |the |following |would |likely |yield |the |greatest
|potential |reduction |in |BP
in |a |patient |with |a |BMI |of |30 |kg/m2?
A. 10-kg |(22-lb) |weight |loss
B. dietary |sodium |restriction |to |2.4 |g |(6 |g |NaCl) |per |day
C. regular |aerobic |physical |activity, |such |as |30 |minutes
|of |brisk |walking |most |days |of |the |week
D. moderation |of |alcohol |consumption
, 11. A |middle-aged |woman |who |has |taken |therapeutic |dose |of |lorazepam |for |the |past |6 |years
|wishes |to |stop |taking
the |medication. |You |advise |her |that:
A. she |can |discontinue |the |drug |immediately |if |she |believes |it |no |longer |helps |with |her
|symptoms.
B. rapid |withdrawal |in |this |situation |can |lead |to |tremors |and |hallucinations.
C. she |should |taper |down |the |dose |of |the |medication |over |the |next |week.
D. gastrointestinal |upset |is |typically |reported
12. Patient |forgetful |would |benefit |from |a |med |that |has |a |long |half |life
|Zoloft
Celexa
Fluoxetine |(Prozac) |has |the |longest |half |life
13. Add |basal |insulin |to |a |patient |already |taking |3 |oral |meds. |Reduce |which |med?
|Metformin
Glipizide |(sulfonylurea)
|TZD
DPP |4 |inhibitor
According |to |slide |13 |on |PEARL
14. Lipid |lowering |moderate |intensity |statins
|Moderate |dose |statin |(avg |LDL |reduction |30-50%)
|Mimi |chose |20-30%
15. An |example |of |an |appropriate |question |to |pose |to |a |person |with |obesity |who |is |in |the
|precontemplation
change |stage |is:
A. “How |do |you |feel |about |your |weight?”
B. “What |are |barriers |you |see |to |losing |weight?”
C. “What |is |your |personal |goal |for |weight |loss?”
D. “How |do |you |envision |my |helping |you |meet |your |weight |loss |goal?”
16. Which |disorder |seen |in |uncontrolled |DM |with |increased |glucose?
|Pancreatitis
Hypothyroidism |???
|Gall |stones
High |triglycerides
